PPMD and Wave Life Sciences hosted a webinar on November 14, 2017 to provide an overview of Wave’s stereopure exon skipping oligonucleotide programs for the treatment of Duchenne muscular dystrophy and an introduction to the planned Phase 1 clinical trial.
by: Parent Project Muscular Dystrophy
